Kura Oncology (KURA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$77.2M

Revenue (quarter)

$20.9M

Revenue growth (year over year)

+36.54%

Gross profit (trailing twelve months)

$76.7M

Gross margin

99.27%

Net income (trailing twelve months)

−$296.8M

Net income (quarter)

−$68.3M

Net income growth (year over year)

−3.33%

Net margin

−384.30%

Return on equity

−167.71%

EPS (trailing twelve months)

−$3.37

Book value per share

$0.54

P/E (trailing twelve months)

—

Price to book

18.00

Debt to assets

91.76%

Payout ratio

—

Dividend yield

—

Company profile

Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

• Is Kura Oncology (KURA) profitable?

  No. Kura Oncology reported a net loss of $296.8M over the trailing twelve months.

• How much revenue does Kura Oncology (KURA) make?

  Kura Oncology generated $77.2M in revenue over the trailing twelve months, up 36.54% year over year.

• How do I buy stock in Kura Oncology (KURA)?

  KURA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.